Biomarker study using cell-free DNA from lEGFR T790M-positive ung adenocarcinoma patients who receive osimertinib + ramucirumab after EGFR-TKI failure

Biomarker study using cell-free DNA from lEGFR T790M-positive ung adenocarcinoma patients who receive osimertinib + ramucirumab after EGFR-TKI failure - Biomarker study in adenocarcinoma patients who receive osimertinib + ramucirumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035642

Enrollment

Registered

2019-01-24

Start date

2017-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who participate in phase I study of osimertinib and ramucirumab and who can provide blood sample and tisuue sample.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Concordance between tumor tissue and cell-free DNA	—

Countries

Japan

Contacts

Public ContactYasuhiro Koh

Wakayama Medical University Internal Medicine III

ykoh@wakayama-med.ac.jp0734410619

Outcome results